New pharmacologic treatments for migraine prevention (13)– (17)
| Drug | Indication | Dosing | Discontinuation rate,* % | Injection-site reactions,* % | Constipation,* % | Incidence of ADA,* (17) % |
|---|---|---|---|---|---|---|
| Erenumab (13) | Episodic and chronic migraine | SC injection; 70 mg or 140 mg monthly | 1.3 | 4.5–5.6 | 1.3–3.2 | 2.0–8.0 |
| Galcanezumab (14) | Episodic and chronic migraine | SC injection; 240 mg loading dose, then 120 mg monthly | 1.8 | 10.6–30.3 | 0.7–1.8 | 3.0–12.0 |
| Fremanezumab (15) | Episodic and chronic migraine | SC injection; 225 mg monthly or 675 mg quarterly | 1.7 | 43.0–45.0 | < 1.0 | 0.3–2.0 |
| Eptinezumab (16) | Episodic and chronic migraine | IV infusion; 100 mg or 300 mg quarterly | 1.9 | < 2.0 (infusion-site reactions) | 0.7–1.2 | 16.0–18.0 |
Note: ADA = antidrug antibodies, IV = intravenous, SC = subcutaneous.
↵* Direct comparisons cannot be made between any of the presented data.